ClinicalTrials.gg
RecruitingNCT07413653VISCERALUpdated Oct 21, 2026

Virtual hIStology of Crohn's Disease Ex-vivo Resected Anatomical Lesions

An observational study in Crohn Disease (CD), sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 21, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Crohn Disease by Central Hospital, Nancy, France — 6 open to participants now, 7 under way, none of them phase 3. Crohn Disease · Central Hospital, Nancy, France.

Started
2026
the only one that year
Observational
7 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Crohn Disease by Central Hospital, Nancy, France, this one is the only one that started in 2026, is one of 7 observational ones, and was the 17th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 17 studies in Crohn Disease by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Crohn Disease by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

Crohn's disease is a chronic, incurable inflammatory bowel disease with an unpredictable course, characterized by alternating remission and inflammatory flares. Current follow-up strategies are poorly suited to early flare detection, leading to uncontrolled disease progression and complications. A major clinical challenge is distinguishing reversible inflammatory activity from irreversible intestinal fibrosis, as existing imaging techniques lack specificity. This study aims to perform comprehensive ex vivo multiparametric MRI, combined with biophysical measurements and histopathology, on resected intestinal specimens to precisely map inflammation and fibrosis and to validate in vivo MRI-derived biomarkers for personalized therapeutic decision-making.

03

Conditions studied

  • Crohn Disease (CD)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (≥18 years) diagnosed with Crohn's disease who are undergoing planned intestinal resection surgery at CHRU Nancy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Diagnosis of Crohn's disease and undergoing intestinal resection surgery at CHRU Nancy.
  • Patient has not objected to the reuse of personal data and biological samples for the purposes of this research.

Exclusion criteria

Exclusion Criteria:

- None

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Crohn's Disease Patients Undergoing Intestinal Resection

    Patients with Crohn's disease undergoing planned intestinal resection surgery. Resected intestinal specimens will be analyzed ex vivo using multiparametric magnetic resonance imaging, biophysical measurements (mechanical and electrical properties), and histopathological examination. No experimental intervention is performed on participants beyond standard surgical care.

06

What researchers measure

Primary outcomes

  1. Ex vivo MRI assessment of intestinal biophysical properties - T2 relaxometry

    Measurement of T2 relaxometry (ms) of resected intestinal tissue using ex vivo MRI.

    Time frame: Baseline (J0): day of surgery

  2. Ex vivo MRI assessment of intestinal biophysical properties - T1 relaxometry

    Measurement of T1 relaxometry (ms) of resected intestinal tissue using ex vivo MRI.

    Time frame: Baseline (J0): day of surgery

  3. Ex vivo MRI assessment of intestinal electrical properties - conductivity

    Measurement of tissue conductivity (S/m) using MR electrical properties tomography (MR-EPT).

    Time frame: Baseline (J0): day of surgery

  4. Ex vivo MRI assessment of intestinal electrical properties - permittivity

    Measurement of tissue relative permittivity (unitless) using MR electrical properties tomography (MR-EPT).

    Time frame: Baseline (J0): day of surgery

  5. Ex vivo MRI assessment of intestinal mechanical properties - elastography

    Measurement of tissue stiffness (kPa) using magnetic resonance elastography.

    Time frame: Baseline (J0): day of surgery

Secondary outcomes

  1. Histopathological quantification of intestinal fibrosis - total area

    Measurement of fibrotic area (mm²) on the entire histological section from the area of maximal stenosis.

    Time frame: Baseline (J0): day of surgery

  2. Histopathological quantification of intestinal inflammation - total area

    Measurement of inflammatory area (mm²) on the entire histological section from the area of maximal stenosis.

    Time frame: Baseline (J0): day of surgery

  3. Association between ex vivo and in vivo MRI lesion characteristics

    Correlation between lesion properties measured ex vivo and in vivo MRI parameters of the same lesions.

    Time frame: Baseline (J0): day of surgery

  4. Association between intestinal lesion characteristics and clinical events

    Correlation between in vivo MRI-derived intestinal lesion characteristics and occurrence of clinical events (emergency visits for abdominal pain, hospitalizations for digestive causes, additional intestinal resection) within 12 months post-surgery.

    Time frame: 12 months post-surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's planned 12 months is below that.

Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Apr 2026 → Sep 2026, primary completion Apr 2027 → Oct 2027 and completion Apr 2028 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartActual
Sep 25, 2026was Apr 2026
Primary completionEst.
Oct 1, 2027was Apr 2027
CompletionEst.
Oct 1, 2028was Apr 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
CHRU Nancy is now Recruiting
Oct 21, 2026
Start date
Apr 1, 2026→Sep 25, 2026 (actual)
Oct 21, 2026
Primary completion
Apr 1, 2027→Oct 1, 2027
Oct 21, 2026
Study completion
Apr 1, 2028→Oct 1, 2028
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    CHRU Nancy is now Recruiting
    Start date Apr 1, 2026→Sep 25, 2026 (now actual)
    Primary completion Apr 1, 2027→Oct 1, 2027
    Study completion Apr 1, 2028→Oct 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07413653
Responsible party
Valérie LAURENT (Principal Investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
Feb 17, 2026
Start date
Sep 25, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Guillaume DROUOT, PhD
Contact
g.drouot@chru-nancy.fr
+33383157666

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion